Suzhou Stainwei Biotechnology

Suzhou Stainwei Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the development of innovative nanobody-based therapeutics. The company utilizes its proprietary nanobody discovery and engineering platform to address unmet medical needs in oncology and infectious diseases. Its pipeline features several high-affinity nanobody candidates, including STW-001 (anti-PD-L1) and STW-002 (anti-CD47), which are designed for improved tissue penetration and multi-specific targeting. Stainwei aims to leverage the structural advantages of single-domain antibodies to create more effective and safer biologics for global patients. The company's technology also extends to diagnostic applications and the development of neutralizing antibodies for viral infections like COVID-19. Supported by investors like Oriza Holdings, Stainwei is positioned as a leader in the Chinese nanobody landscape.